Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesenas Chief Medical Officer

  • Dr. Ottesen brings in-depth global clinical development expertise in oncology, including biologics, small molecules, immunotherapies and ADCs
  • Adcendo further builds its world class team to accelerate development of lead ADC asset uPARAP and to expand its first-in-class ADC pipeline

Copenhagen, Denmark, June 20, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, is pleased to announce the appointment of Dr. Lone H. Ottesen as Chief Medical Officer (CMO).

Read more…